Age-related macular degeneration is a common, chronic, progressive, degenerative disease that causes central loss of vision due to abnormalities that occurs in the pigment, neural and vascular layers of the macula.
The macular disorder may have one or more of the following:
- Formation of drusen which are localized deposits of extracellular material usually concentrated in the macula
- Abnormalities in the retinal pigment epithelium (eg hypopigmentation or hyperpigmentation)
- Retinal pigment epithelium and choriocapillaris geographic atrophy
- Neovascular (exudative) maculopathy
Decreased central vision and distortion of seeing straight lines are the most common symptoms.
Increased dietary intake of multiple nutrients, such as minerals, vitamins, and carotenoids, protects against the risk of progression to late age-related macular degeneration, specifically geographic atrophy, according to a study.
The risk of developing myopic macular degeneration (MMD) is high among older individuals, women, those with lower education, greater myopia severity, and longer axial length, according to data from a consortium of Asian studies. Furthermore, myopic spherical equivalent is the strongest single predictor of MMD.
Dr. David Eichenbaum, Dr. Dilsher Dhoot, Prof. Peter Campochiaro, Dr. Timothy Y Y Lai, 20200904062030
Intravitreal injection of antiangiogenic agents is the standard of care for neovascular age-related macular degeneration (nAMD), however, frequent injections represent a considerable treatment burden for patients. Results of the Ladder and Archway studies, presented at the 38th Annual Meeting of the American Society of Retina Specialists (ASRS 2020), showed that administration of ranibizumab through a port delivery system (PDS) considerably reduced treatment burden, while maintaining comparable efficacy and safety vs intravitreal injections. In an interview with MIMS Doctor, Dr Timothy Lai of Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong, discusses how PDS may transform the management of nAMD.
For patients with neovascular age-related macular degeneration (nAMD), a less frequent dosing regimen of abicipar appears to improve and stabilize visual acuity over 52 weeks of treatment, and this effect is noninferior to that of monthly ranibizumab injections, as shown in the results of two phase III trials.
When choosing between ranibizumab and aflibercept for treating neovascular age-related macular degeneration, neither drug bests the other in terms of visual acuity outcomes and treatment frequency at 3 years, according to data from the Fight Retinal Blindness! Registry.
Adding rescue photodynamic therapy (rPDT) to treatment with the anti-VEGF agent aflibercept intravitreally did not provide additional benefit for patients with polypoidal choroidal vasculopathy (PCV), a type of neovascular age-related macular degeneration (nAMD), according to the PLANET study, suggesting that aflibercept monotherapy sufficed for these patients.
Higher adherence to the Mediterranean Diet (MedDiet) results in a 41-percent reduced risk of incident advanced age-related macular degeneration (AMD), according to pooled data from the Rotterdam Study I (RS-I) and Alienor* Study.
Following a diet consisting of vegetables 200 g per day, fruit two times per day and fish two times per week is good advice for individuals at risk of age-related macular degeneration (AMD), as it yields a significant reduction in the risk of the eye disease, according to a recent study.
Intravitreal injection of antivascular endothelial growth factor (anti-VEGF) therapy is a safe and effective treatment for neovascular age-related macular degeneration (AMD) over 2 years, the period for which data are available in this literature review.
Age-related macular degeneration is strongly associated with high-density lipoprotein cholesterol and triglycerides, with the magnitude of effect being higher for early disease and related to drusen size and area, a study has found.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.